{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:19:08Z","timestamp":1790090348261,"version":"4.0.1"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.ejphar.2019.172729","type":"journal-article","created":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T11:03:01Z","timestamp":1570618981000},"page":"172729","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["The angiotensin converting enzyme inhibitor captopril attenuates testosterone-induced benign prostatic hyperplasia in rats; a mechanistic approach"],"prefix":"10.1016","volume":"865","author":[{"given":"Fatma","family":"Mostafa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman M.","family":"Mantawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar S.","family":"Azab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebtehal","family":"El-Demerdash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ejphar.2019.172729_bib1","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1002\/ptr.5936","article-title":"Inhibitory effect of thymoquinone on testosterone-induced benign prostatic hyperplasia in wistar rats","volume":"31","author":"Al-Trad","year":"2017","journal-title":"Phytother Res."},{"issue":"4","key":"10.1016\/j.ejphar.2019.172729_bib2","first-page":"247","article-title":"Effect of captopril on TNF-\u03b1 and IL-10 in the livers of bile duct ligated rats","volume":"7","author":"Amirshahrokhi","year":"2010","journal-title":"Iran J Immunol"},{"issue":"7","key":"10.1016\/j.ejphar.2019.172729_bib3","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/pros.22951","article-title":"The effect of pomegranate fruit extract on testosterone-induced BPH in rats","volume":"75","author":"Ammar","year":"2015","journal-title":"The Prostate"},{"issue":"12","key":"10.1016\/j.ejphar.2019.172729_bib4","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s00210-014-1040-y","article-title":"Modulatory effect of silymarin on inflammatory mediators in experimentally induced benign prostatic hyperplasia: emphasis on PTEN, HIF-1\u03b1, and NF-\u03baB","volume":"387","author":"Atawia","year":"2014","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"2","key":"10.1016\/j.ejphar.2019.172729_bib5","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.toxlet.2013.03.002","article-title":"Role of the phytoestrogenic, pro-apoptotic and anti-oxidative properties of silymarin in inhibiting experimental benign prostatic hyperplasia in rats","volume":"219","author":"Atawia","year":"2013","journal-title":"Toxicol. Lett."},{"issue":"8","key":"10.1016\/j.ejphar.2019.172729_bib6","doi-asserted-by":"crossref","first-page":"E1436","DOI":"10.1210\/jc.2013-3636","article-title":"Nuclear factor \u03baB-dependent regulation of angiogenesis, and metastasis in an in vivo model of thyroid cancer is associated with secreted interleukin-8","volume":"99","author":"Bauerle","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"22","key":"10.1016\/j.ejphar.2019.172729_bib7","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1038\/sj.onc.1204343","article-title":"Inhibition of the NF-kappa B transcription factor increases Bax expression in cancer cell lines","volume":"20","author":"Bentires-Alj","year":"2001","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.ejphar.2019.172729_bib8","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1073\/pnas.91.8.2890","article-title":"T lymphocytes synthesize and export heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor, mitogens for vascular cells and fibroblasts: differential production and release by CD4+ and CD8+ T cells","volume":"91","author":"Blotnick","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.ejphar.2019.172729_bib9","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0008-6363(01)00220-6","article-title":"Inhibition of transcription factor NF-kappaB reduces matrix metalloproteinase-1, -3 and -9 production by vascular smooth muscle cells","volume":"50","author":"Bond","year":"2001","journal-title":"Cardiovasc. Res."},{"issue":"1","key":"10.1016\/j.ejphar.2019.172729_bib10","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1128\/AAC.01335-15","article-title":"Structural basis of metallo-\u03b2-lactamase inhibition by captopril stereoisomers","volume":"60","author":"Brem","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"13","key":"10.1016\/j.ejphar.2019.172729_bib11","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.eursup.2009.11.002","article-title":"Benign prostatic hyperplasia and its aetiologies","volume":"8","author":"Briganti","year":"2009","journal-title":"Eur. Urol. Suppl."},{"issue":"4 Suppl. 1","key":"10.1016\/j.ejphar.2019.172729_bib12","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0090-4295(03)00045-1","article-title":"The role of dihydrotestosterone in benign prostatic hyperplasia","volume":"61","author":"Carson","year":"2003","journal-title":"Urology"},{"issue":"1\u20132","key":"10.1016\/j.ejphar.2019.172729_bib13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1023\/A:1026057402945","article-title":"The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer","volume":"253","author":"Chatterjee","year":"2003","journal-title":"Mol. Cell. Biochem."},{"issue":"16031","key":"10.1016\/j.ejphar.2019.172729_bib14","first-page":"1","article-title":"Benign prostatic hyperplasia","volume":"2","author":"Chughtai","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"10.1016\/j.ejphar.2019.172729_bib15","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s00394-016-1169-1","article-title":"Flaxseed reduces epithelial proliferation but does not affect basal cells in induced benign prostatic hyperplasia in rats","volume":"56","author":"de Amorim Ribeiro","year":"2017","journal-title":"Eur. J. Nutr."},{"issue":"3","key":"10.1016\/j.ejphar.2019.172729_bib16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/pros.2990260302","article-title":"Microvascularity in benign prostatic hyperplasia","volume":"26","author":"Deering","year":"1995","journal-title":"The Prostate"},{"issue":"2","key":"10.1016\/j.ejphar.2019.172729_bib17","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1046\/j.1523-1747.2000.00034.x","article-title":"Delayed wound healing in CXCR2 knockout mice","volume":"115","author":"Devalaraja","year":"2000","journal-title":"J. Investig. Dermatol."},{"issue":"2","key":"10.1016\/j.ejphar.2019.172729_bib18","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/path.1021","article-title":"Evidence for activation of the renin-angiotensin system in the human prostate: increased angiotensin II and reduced AT(1) receptor expression in benign prostatic hyperplasia","volume":"196","author":"Dinh","year":"2002","journal-title":"J. Pathol."},{"issue":"3","key":"10.1016\/j.ejphar.2019.172729_bib19","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s13105-016-0489-1","article-title":"A common effect of angiotensin II and relaxin 2 on the PNT1A normal prostate epithelial cell line","volume":"72","author":"Domi\u0144ska","year":"2016","journal-title":"J. Physiol. Biochem."},{"issue":"2\u20133","key":"10.1016\/j.ejphar.2019.172729_bib20","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.bbamcr.2003.08.011","article-title":"Control of mitochondrial integrity by Bcl-2 family members and caspase-independent cell death","volume":"1644","author":"Donovan","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"issue":"1","key":"10.1016\/j.ejphar.2019.172729_bib21","first-page":"408","article-title":"Captopril and telmisartan ameliorate cisplatin-induced testicular damage in rats via anti-inflammatory and antioxidant pathways","volume":"6","author":"Eid","year":"2016","journal-title":"International Journal of Scientific and Research Publications"},{"issue":"234","key":"10.1016\/j.ejphar.2019.172729_bib22","first-page":"1","article-title":"Management of benign prostatic hyperplasia: could dietary polyphenols Be an alternative to existing therapies?","volume":"8","author":"Eleazu","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.ejphar.2019.172729_bib23","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3109\/21681805.2015.1044560","article-title":"Tumor necrosis factor-\u03b1 expression in patients with obstructive benign prostatic hyperplasia is associated with a higher incidence of asymptomatic inflammatory prostatitis NIH category IV and prostatic calcification","volume":"49","author":"Engelhardt","year":"2015","journal-title":"Scand J Urol"},{"issue":"3","key":"10.1016\/j.ejphar.2019.172729_bib24","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2605.2009.00972.x","article-title":"Chronic inflammation in the pathogenesis of benign prostatic hyperplasia","volume":"33","author":"Fibbi","year":"2010","journal-title":"Int. J. Androl."},{"issue":"11","key":"10.1016\/j.ejphar.2019.172729_bib25","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nrc2945","article-title":"The renin-angiotensin system and cancer: old dog, new tricks","volume":"10","author":"George","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.ejphar.2019.172729_bib26","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0002-9440(10)61681-1","article-title":"Interleukin-8 is a paracrine inducer of fibroblast growth factor 2, a stromal and epithelial growth factor in benign prostatic hyperplasia","volume":"159","author":"Giri","year":"2001","journal-title":"Am. J. Pathol."},{"issue":"24","key":"10.1016\/j.ejphar.2019.172729_bib27","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1038\/sj.onc.1205483","article-title":"NF-kB activates Bcl-2 expression in t(14;18) lymphoma cells","volume":"21","author":"Heckman","year":"2002","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.ejphar.2019.172729_bib28","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1210\/me.2004-0536","article-title":"Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II","volume":"20","author":"Hunyady","year":"2006","journal-title":"Mol. Endocrinol."},{"issue":"Suppl. 1","key":"10.1016\/j.ejphar.2019.172729_bib29","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000475324","article-title":"Etiology of benign prostatic hyperplasia","volume":"25","author":"Isaacs","year":"1994","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejphar.2019.172729_bib30","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/fcp.12304","article-title":"Potential of telmisartan in the treatment of benign prostatic hyperplasia","volume":"6","author":"Ishola","year":"2017","journal-title":"Fundam. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejphar.2019.172729_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4172\/2167-065X.1000169","article-title":"Beneficial effect of a multifunctional polyphytocompound in experimental prostatic hyperplasia in rats","volume":"6","author":"Kantah","year":"2017","journal-title":"Clin. Pharmacol. Biopharm."},{"issue":"5","key":"10.1016\/j.ejphar.2019.172729_bib32","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/15376516.2016.1191576","article-title":"Effect of captopril and telmisartan on methotrexate-induced hepatotoxicity in rats: impact of oxidative stress, inflammation and apoptosis","volume":"26","author":"Kelleni","year":"2016","journal-title":"Toxicol. Mech. Methods"},{"key":"10.1016\/j.ejphar.2019.172729_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12906-015-0825-y","article-title":"Inhibitory effect of curcumin on testosterone induced benign prostatic hyperplasia rat model","volume":"15","author":"Kim","year":"2015","journal-title":"BMC Complement Altern. Med."},{"issue":"Pt 4","key":"10.1016\/j.ejphar.2019.172729_bib34","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1242\/jcs.00286","article-title":"VEGF expression in human macrophages is NF-kappaB-dependent: studies using adenoviruses expressing the endogenous NF-kappaB inhibitor IkappaBalpha and a kinase-defective form of the IkappaB kinase 2","volume":"116","author":"Kiriakidis","year":"2003","journal-title":"J. Cell Sci."},{"issue":"5","key":"10.1016\/j.ejphar.2019.172729_bib35","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.eururo.2006.12.011","article-title":"Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?","volume":"51","author":"Kramer","year":"2007","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejphar.2019.172729_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/454783","article-title":"Synergistic inhibition of angiogenesis by artesunate and captopril in vitro and in vivo","volume":"2013","author":"Krusche","year":"2013","journal-title":"Evid Based Complement Alternat Med"},{"issue":"2","key":"10.1016\/j.ejphar.2019.172729_bib37","first-page":"79","article-title":"Pathophysiology of benign prostate enlargement and lower urinary tract symptoms: current concepts","volume":"29","author":"Lee","year":"2017","journal-title":"Ci Ji Yi Xue Za Zhi"},{"issue":"3","key":"10.1016\/j.ejphar.2019.172729_bib38","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1677\/jme.0.0300263","article-title":"The renin-angiotensin system and male reproduction: new functions for old hormones","volume":"30","author":"Leung","year":"2003","journal-title":"J. Mol. Endocrinol."},{"issue":"1","key":"10.1016\/j.ejphar.2019.172729_bib39","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3892\/etm.2014.1723","article-title":"Qianliening capsule inhibits benign prostatic hyperplasia angiogenesis via the HIF-1\u03b1 signaling pathway","volume":"8","author":"Lin","year":"2014","journal-title":"Exp Ther Med"},{"issue":"6","key":"10.1016\/j.ejphar.2019.172729_bib40","doi-asserted-by":"crossref","first-page":"6765","DOI":"10.18632\/oncotarget.6837","article-title":"Is angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers therapy protective against prostate cancer?","volume":"7","author":"Mao","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejphar.2019.172729_bib41","first-page":"1","article-title":"Androgens rapidly activate nuclear factor-kappa B via intracellular Ca2+ signalling in human vascular endothelial cells","volume":"S:2","author":"McGrath","year":"2012","journal-title":"J. Steroids Hormonal Sci."},{"issue":"21","key":"10.1016\/j.ejphar.2019.172729_bib42","first-page":"1","article-title":"Captopril reduces cardiac inflammatory markers in spontaneously hypertensive rats by inactivation of NF-kB","volume":"7","author":"Miguel-Carrasco","year":"2010","journal-title":"J. Inflamm."},{"issue":"2","key":"10.1016\/j.ejphar.2019.172729_bib43","first-page":"1","article-title":"Renin-angiotensin system and cancer: a review","volume":"4","author":"Munro","year":"2017","journal-title":"Integr Cancer Sci Therap"},{"issue":"1","key":"10.1016\/j.ejphar.2019.172729_bib44","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ucl.2007.09.012","article-title":"Inflammation and benign prostatic hyperplasia","volume":"35","author":"Nickel","year":"2008","journal-title":"Urol. Clin. N. Am."},{"issue":"4","key":"10.1016\/j.ejphar.2019.172729_bib45","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.eursup.2006.02.003","article-title":"Inflammation, apoptosis, and BPH: what is the evidence?","volume":"5","author":"Novara","year":"2006","journal-title":"Eur. Urol. Suppl."},{"issue":"4","key":"10.1016\/j.ejphar.2019.172729_bib46","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000209829","article-title":"Interleukin-10, interferon-& gamma; and tumor necrosis factor-& alpha; genes variation in prostate cancer and benign prostatic hyperplasia","volume":"2","author":"Omrani","year":"2009","journal-title":"Current Urology"},{"issue":"3","key":"10.1016\/j.ejphar.2019.172729_bib47","first-page":"108","article-title":"The proteins and the mechanisms of apoptosis: a mini-review of the fundamentals","volume":"11","author":"Papaliagkas","year":"2007","journal-title":"Hippokratia"},{"issue":"1_supplement","key":"10.1016\/j.ejphar.2019.172729_bib48","article-title":"Effect of enalapril and losartan on testosterone-induced benign prostatic hyperplasia in rats. Pharmacology\/experimental therapeutics","volume":"27","author":"Patel","year":"2013","journal-title":"Faseb Science Research Conference Series"},{"issue":"3","key":"10.1016\/j.ejphar.2019.172729_bib49","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1152\/physrev.00036.2005","article-title":"Physiology of local renin-angiotensin systems","volume":"86","author":"Paul","year":"2006","journal-title":"Physiol. Rev."},{"issue":"4","key":"10.1016\/j.ejphar.2019.172729_bib50","doi-asserted-by":"crossref","first-page":"252","DOI":"10.5173\/ceju.2011.04.art14","article-title":"Immunohistochemical detection of angiotensin AT 1 and AT 2 receptors in prostate cancer","volume":"64","author":"Pawlikowski","year":"2011","journal-title":"Cent European J Urol"},{"issue":"4","key":"10.1016\/j.ejphar.2019.172729_bib51","first-page":"341","article-title":"The involvement of angiotensins in the control of prostatic epithelial cell proliferation in the rat","volume":"39","author":"Pawlikowski","year":"2001","journal-title":"Folia Histochem. Cytobiol."},{"issue":"1","key":"10.1016\/j.ejphar.2019.172729_bib52","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1080\/00365590802468875","article-title":"Captopril may reduce biochemical (prostate-specific antigen) failure following radical prostatectomy for clinically localized prostate cancer","volume":"43","author":"Ronquist","year":"2009","journal-title":"Scand. J. Urol. Nephrol."},{"issue":"1","key":"10.1016\/j.ejphar.2019.172729_bib53","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/pros.10294","article-title":"Association between captopril, other antihypertensive drugs and risk of prostate cancer","volume":"58","author":"Ronquist","year":"2004","journal-title":"The Prostate"},{"key":"10.1016\/j.ejphar.2019.172729_bib54","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.taap.2016.09.024","article-title":"Dapoxetine attenuates testosterone-induced prostatic hyperplasia in rats by the regulation of inflammatory and apoptotic proteins","volume":"311","author":"Sayed","year":"2016","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"12","key":"10.1016\/j.ejphar.2019.172729_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0168312","article-title":"Atorvastatin, losartan and captopril lead to upregulation of TGF-\u03b2, and downregulation of IL-6 in coronary artery disease and hypertension","volume":"11","author":"Sepehri","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ejphar.2019.172729_bib56","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3181\/0707-MR-196","article-title":"Nuclear factor-\u03bab activation: from bench to bedside","volume":"233","author":"Sethi","year":"2008","journal-title":"Exp. Biol. Med."},{"issue":"5","key":"10.1016\/j.ejphar.2019.172729_bib57","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1097\/01.ju.0000176459.79180.d1","article-title":"Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia","volume":"174","author":"Shariat","year":"2005","journal-title":"J. Urol."},{"issue":"12","key":"10.1016\/j.ejphar.2019.172729_bib58","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/mnfr.200700197","article-title":"In vitro and in vivo modulation of testosterone mediated alterations in apoptosis related proteins by [6]-gingerol","volume":"51","author":"Shukla","year":"2007","journal-title":"Mol. Nutr. Food Res."},{"issue":"2","key":"10.1016\/j.ejphar.2019.172729_bib59","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0022-5347(17)34998-4","article-title":"Phenotype and function of peripheral and prostatic lymphocytes in patients with benign prostatic hyperplasia","volume":"151","author":"Steiner","year":"1994","journal-title":"J. Urol."},{"issue":"6","key":"10.1016\/j.ejphar.2019.172729_bib60","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S1357-2725(02)00271-6","article-title":"Inflammation and angiotensin II","volume":"35","author":"Suzuki","year":"2003","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"6","key":"10.1016\/j.ejphar.2019.172729_bib61","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1097\/01.LAB.0000017372.76297.EB","article-title":"Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor-and inflammation-related pathways","volume":"82","author":"Tamarat","year":"2002","journal-title":"Lab. Investig."},{"issue":"3","key":"10.1016\/j.ejphar.2019.172729_bib62","doi-asserted-by":"crossref","first-page":"312","DOI":"10.4103\/0970-1591.56179","article-title":"Etiopathogenesis of benign prostatic hyperplasia","volume":"25","author":"Tang","year":"2009","journal-title":"Indian J. Urol."},{"issue":"11","key":"10.1016\/j.ejphar.2019.172729_bib63","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1158\/1535-7163.MCT-04-0295","article-title":"Antiproliferative activity of angiotensin II receptor blocker through cross-talk between stromal and epithelial prostate cancer cells","volume":"4","author":"Uemura","year":"2005","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejphar.2019.172729_bib64","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1146\/annurev.immunol.021908.132641","article-title":"Regulation and function of NF-\u03baB transcription factors in the immune system","volume":"27","author":"Vallabhapurapu","year":"2009","journal-title":"Annu. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.ejphar.2019.172729_bib65","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0092-8674(04)00166-7","article-title":"Tumor necrosis factor: an apoptosis JuNKie?","volume":"116","author":"Varfolomeev","year":"2004","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.ejphar.2019.172729_bib66","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1172\/JCI118838","article-title":"Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats","volume":"98","author":"Volpert","year":"1996","journal-title":"J. Clin. Investig."},{"issue":"5383","key":"10.1016\/j.ejphar.2019.172729_bib67","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1126\/science.281.5383.1680","article-title":"NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation","volume":"281","author":"Wang","year":"1998","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.ejphar.2019.172729_bib68","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/1470320313496858","article-title":"The renin-angiotensin system meets the hallmarks of cancer","volume":"16","author":"Wegman-Ostrosky","year":"2015","journal-title":"J. Renin-Angiotensin-Aldosterone Syst. JRAAS"},{"issue":"6","key":"10.1016\/j.ejphar.2019.172729_bib69","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1046\/j.1523-1755.2002.00365.x","article-title":"Angiotensin II activates nuclear transcription factor-kappaB through AT1 and AT2 receptors","volume":"61","author":"Wolf","year":"2002","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2019.172729_bib70","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.toxlet.2016.11.011","article-title":"The anti-hyperplasia, anti-oxidative and anti-inflammatory properties of Qing Ye Dan and swertiamarin in testosterone-induced benign prostatic hyperplasia in rats","volume":"265","author":"Wu","year":"2017","journal-title":"Toxicol. Lett."},{"issue":"3","key":"10.1016\/j.ejphar.2019.172729_bib71","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0009-8981(80)90274-0","article-title":"Angiotensin-converting enzyme in human prostate","volume":"100","author":"Yokoyama","year":"1980","journal-title":"Clin. Chim. Acta"},{"issue":"3","key":"10.1016\/j.ejphar.2019.172729_bib72","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.bbrc.2005.03.189","article-title":"The transcriptional targets of p53 in apoptosis control","volume":"331","author":"Yu","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299919306818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299919306818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:31:36Z","timestamp":1757975496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299919306818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":72,"alternative-id":["S0014299919306818"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2019.172729","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The angiotensin converting enzyme inhibitor captopril attenuates testosterone-induced benign prostatic hyperplasia in rats; a mechanistic approach","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2019.172729","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"172729"}}